Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Exec appointment
confidence 88%
filed 2026-07-02
Item 5.02
Lucid announced multiple senior executive appointments to its Global Leadership Team, including Alexander De Bock as Chief Financial Officer (with $750,000 base salary, $1.1M signing bonus, $7.5M equity grants, and up to $2.5M performance-based bonuses), Raja Ramana Macha as Chief Technology Officer, Billy Hayes as Chief Customer Officer, Hugo Martinho as Chief Transformation Officer, Kay Stepper as Chief Digital Officer, and a promotion of Christian Appel, alongside the departure of incumbent CFO Taoufiq Boussaid. These appointments are intended to simplify the organization, sharpen accountability, and improve execution.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-02
Item 3.02
The Company completed an unregistered private placement of 352,179 Class J common shares for approximately $7.1 million under Section 4(a)(2) and Regulation D Rule 506, and issued 3,259.24 Class E common shares to an affiliate as payment for advisory fees, representing a significant dilutive equity issuance.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-07-02
Item 7.01
The Company declared distributions to shareholders of both Class J and Class E common shares at $0.17 per share, payable on or about July 20, 2026, with a record date and reinvestment plan option available.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-07-02
Item 1.01
Centrus signed a material definitive contract with the U.S. Department of Energy on June 30, 2026, establishing a $900 million firm fixed-price agreement to deploy HALEU enrichment capacity with performance-based milestone payments through March 2032, plus options for up to $170 million in additional purchases (total contract value $1.07 billion with all options). This represents a significant material transaction that would affect investor assessment of the company's revenue prospects, capital deployment, and strategic positioning in the domestic uranium enrichment market.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-07-02
Item 5.02
The disclosure centers on compensatory arrangements for three named executives: base salary increases for Burnette (from $425k to $525k), Datta (from $400k to $450k), and Wiesinger (from $400k to $450k); an increase in Burnette's annual incentive bonus opportunity from 80% to 100% of base salary; and substantial equity grants totaling $12 million in restricted stock units under the 2025 Equity Incentive Plan, plus a replacement RSU grant to Datta in exchange for cancellation of a prior option. These are material compensation modifications approved by the Compensation Committee on July 1, 2026.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 72%
filed 2026-07-02
Item 1.01
Backblaze amended its credit agreement with Citizens Bank to expand the indebtedness threshold for capital leases to $150 million. While technically an amendment to an existing facility rather than a new debt issuance, this modification materially increases the Company's borrowing capacity and financial obligations, making it a significant capital structure event. The amendment signals the Company's intent to leverage capital leases as a financing mechanism, which is a material financial obligation creation event.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-07-02
Item 1.01
Abacus Global Management entered into a First Amendment to its Credit Agreement on June 29, 2026, under which lenders agreed to provide incremental term loans of $75,000,000, increasing total aggregate principal from $150,000,000 to $225,000,000.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-07-02
Item 5.02
Sean McNealy resigned from his role as a director of Abacus Global Management, Inc., effective June 30, 2026, in connection with his planned retirement, with planned resignation from all subsidiary roles by December 31, 2026.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-07-02
Item 1.01
TD SYNNEX entered into a European receivables securitization program on June 26, 2026, creating a new direct financial obligation through the issuance of senior and junior notes with an aggregate committed facility of EUR 650 million. This is a material debt issuance under Item 1.01, distinct from a covenant breach or other financial event, as it represents the creation of new financing obligations with defined terms, interest accrual, and amortization schedules extending to June 2028 (potentially 2031).
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-07-02
Item 5.02
Marcy Klevorn resigned from the Board of Directors effective July 1, 2026, after notifying the Board on June 28, 2026. She served on the Compensation Committee and Nominating and Governance Committee. Board departures are material governance events affecting the composition and oversight structure of the company, and the filing explicitly discloses this resignation under Item 5.02 as a director departure.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 85%
filed 2026-07-02
Item 5.02
The disclosure centers on compensatory arrangements for Mr. Loïc Eloy, a named executive officer and President of Nuclear & Safety Group, including a specified annual base salary of USD 415,000, a 50% target bonus opportunity, and customary expatriation-related benefits (housing, relocation, education, travel, tax and social protection). While the filing is under Item 5.02, the principal action disclosed is the modification of his compensation package in connection with his secondment assignment, not a departure or appointment to a new role.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 75%
filed 2026-07-02
Item 7.01
The Board approved an extension of DocGo's share repurchase program from June 30, 2026 to December 31, 2026, allowing continued discretionary purchases of up to $26 million in common stock. While share repurchases are technically distinct from dividends, they constitute a return of capital to shareholders and fall within the dividend_distribution taxonomy as a capital allocation mechanism. The extension of an existing program with material dollar authorization qualifies as material to investors assessing capital allocation strategy.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-07-02
EX-99.1
This announcement discloses a successful Type B meeting with the FDA regarding the ProstACT Global Phase 3 trial of TLX591-Tx, with FDA alignment on advancement into Part 2 in the United States. The disclosure covers regulatory approval of the clinical protocol, statistical framework, and safety data sufficiency to proceed with U.S. enrollment. This is a material operational/regulatory milestone for a clinical-stage therapeutic candidate in a pivotal trial, affecting the company's development timeline and commercial prospects, but does not fit the specific event types (e.g., it is not a discrete M&A activity, earnings release, or executive change).
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 85%
filed 2026-07-02
Item 1.01
Haverty Furniture entered into a Sixth Amendment to its credit agreement, extending the maturity date of the Revolving Credit Facility to June 29, 2031, increasing aggregate commitments from $80 million to $100 million, and raising the swingline sublimit from $5 million to $10 million. This material modification expands the Company's borrowing capacity and extends its debt obligations.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-02
Item 5.02
The filing discloses multiple executive appointments effective July 1, 2026: Robert Wright appointed Chief Financial Officer (replacing Mark Hobbs), Misty Lavender appointed Executive Vice President, General Counsel and Corporate Secretary (replacing Denise McWatters), and Mohit Bhardwaj appointed to a new Executive Vice President, New Energy role. While the section also includes compensation amendments and a departure (McWatters transitioning to consulting), the principal disclosed actions center on the appointments of new officers to key leadership positions, making exec_appointment the most salient classification.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-07-02
Item 3.01
Boxlight received written notice from Nasdaq on July 1, 2026, that its securities are subject to suspension and delisting due to non-compliance with the $2.5 million stockholders' equity requirement under Nasdaq Listing Rule 5550(b). The company plans to request a hearing before the Nasdaq Hearings Panel but acknowledges "there can be no assurance that the Panel will grant the Company's request for continued listing." This is a direct delisting notice triggering Item 3.01 disclosure and represents a material threat to the company's continued public trading status.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-07-02
Item 7.01
The filing discloses the Company's plan to issue its earnings release for the quarter ended June 30, 2026, on July 20, 2026, and host a conference call on July 21, 2026 with Chairman and CEO John W. Bordelon, President Darren E. Guidry, and CFO David T. Kirkley to discuss second quarter results. Although this is technically an announcement of a future earnings release rather than the release itself, the substance is a disclosure of material quarterly financial results, which is a standard earnings_release event.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-07-02
EX-99.1
This press release announces NMPA (China's drug regulator) conditional approval of ORPATHYS® (savolitinib) for MET-amplified gastric cancer, marking the third approved indication for the drug in China. The approval is a significant regulatory and commercial milestone for HUTCHMED's proprietary drug platform, supported by pivotal Phase II trial data published in Nature Medicine. While not a discrete M&A, financing, or governance event, this regulatory approval of a marketed therapeutic product represents a material operational and strategic achievement that would affect a reasonable investor's assessment of the company's pipeline execution and commercial prospects.
View raw filing on EDGAR →
6-K
Dividend Distribution
confidence 92%
filed 2026-07-02
The 6-K announces an update to a share buyback programme authorized to return up to €1 billion to shareholders. The second tranche of €500 million is expected to commence on 6 July 2026 and run through 18 December 2026, with Goldman Sachs acting as riskless principal. Share buyback programmes that return capital to shareholders are classified as dividend distributions under the taxonomy, and a €1 billion capital return programme is material to investors assessing the company's capital allocation and shareholder returns.
View raw filing on EDGAR →
6-K
Debt Issuance
confidence 75%
filed 2026-07-02
This is a notice of redemption for US$3.0 billion in senior unsecured notes (US$2.3 billion fixed/floating rate notes due 2027 and US$700 million floating rate notes due 2027). While technically a redemption rather than a new issuance, it represents a material debt event involving the retirement of a direct financial obligation. The redemption date is 14 August 2026 at par (US$1,000 per US$1,000 principal), with accrued interest payable. This is a material capital event affecting HSBC's debt structure and liquidity position.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-07-02
EX-99.1
The press release announces the appointment of Marvin Singer to the board of directors as the representative for Ataraxia Capital, pursuant to an Investor's Rights Agreement. This is a clear executive/governance appointment of a director with relevant experience in corporate law, M&A, and corporate governance. Board appointments are material to investors as they affect governance and oversight.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-07-02
The 6-K discloses that Nasdaq has granted Integrated Media Technology Limited an additional 180-day cure period (until December 29, 2026) to regain compliance with the minimum bid price requirement of $1 per share under Nasdaq Listing Rule 5550(a)(2). The company failed to regain compliance during the initial 180-day period (which ended June 29, 2026) and now faces a material delisting risk if it cannot achieve ten consecutive business days at or above $1 per share during the extended period. This is a classic delisting-risk disclosure under Item 3.01 equivalent.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-07-02
Item 5.07
Braze held its Annual Meeting of Stockholders on June 30, 2026, with shareholders voting on four proposals: election of directors (Neeraj Agrawal and Yvonne Wassenaar), advisory vote on named executive officer compensation, ratification of Ernst & Young LLP as independent auditor, and approval of a certificate amendment regarding officer exculpation. Voting tallies for each matter were disclosed.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-07-02
Item 5.02
Michael Krawitz, Executive Vice President, General Counsel and Corporate Secretary, is resigning effective July 31, 2026. This is a clear departure of a named executive officer from a senior leadership position. The filing explicitly states his resignation and the effective date, with no indication of a replacement appointment in this section, making the departure the principal disclosed action.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-02
Item 7.01
CNS Pharmaceuticals disclosed a strategic pivot and asset acquisition strategy through an investor presentation posted on July 2, 2026. The presentation outlines a comprehensive corporate restructuring—including a new executive team, a $22.5 million financing closed in May 2026, and a disciplined asset acquisition strategy targeting oncology and neurology assets. While the filing itself is a Regulation FD disclosure of the presentation, the underlying events (strategic refocus, new leadership, capital raise, and asset search) constitute material operational and strategic changes that would affect a reasonable investor's assessment of the company's direction and value creation prospects.
View raw filing on EDGAR →
8-K
Governance Other
confidence 85%
filed 2026-07-02
Item 5.03
Kartoon Studios' Board unanimously adopted a limited-duration stockholder rights plan (poison pill) effective July 13, 2026, and declared a dividend distribution of one right per outstanding share of common stock. The rights plan imposes significant dilution on any person acquiring 10% or more of common stock without Board approval through flip-in and flip-over provisions, materially affecting shareholder rights and takeover defense dynamics.
View raw filing on EDGAR →
8-K
Governance Other
confidence 65%
filed 2026-07-02
Item 3.03
The company disclosed a material modification to the rights of security holders, with details incorporated from Item 5.03 regarding amendments to articles of incorporation or bylaws. The specific nature of the modification affects the fundamental rights or privileges of security holders.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-07-02
Item 1.01
The filing discloses a material supplement to a supply and distribution agreement whereby GPM assumed $2.0 million in accounts payable and acquired equivalent inventory from iPower, and both parties were released from exclusive sourcing and distribution obligations. This represents a material restructuring of the commercial relationship between iPower and its formerly wholly-owned subsidiary, involving a significant transfer of liabilities and assets that would affect investor assessment of the company's financial position and operational structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-02
Item 5.02
Simon Kearney was elected to Nixxy's Board of Directors on June 29, 2026. The disclosure centers on his appointment as a director and includes his background, compensation structure (50,000 initial shares, annual equity grants, and $2,500 monthly payment), and confirmations of no conflicts or family relationships. This is a clear director appointment event.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-07-02
Item 1.01
AppTech Payments entered into a $500,000 Promissory Note on June 26, 2026, creating a direct financial obligation. The Note bears 9.0% interest and matures in 90 days, representing a material new debt obligation disclosed under Item 1.01 and Item 2.03. The related-party nature (lender is a trust controlled by the Board Chairman) and short-term working capital purpose are disclosed but do not change the fundamental character of the event as debt issuance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-02
Item 5.02
The filing discloses the appointment of Kathryn Masci and Daniel Plourde as Co-Chief Financial Officers of Grayscale Investments Sponsors, LLC (the sponsor) on an interim basis, effective July 2, 2026, with Ms. Masci also appointed as Principal Financial and Accounting Officer of the registrant and as a member of the Board of Managers. While the filing also mentions Edward McGee's departure, the principal disclosed action centers on the two new appointments to critical financial leadership roles. This is material as it affects the registrant's financial reporting and governance structure.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-07-02
Item 5.07
This Item 5.07 discloses the results of the Annual Meeting of Stockholders held on June 30, 2026, including voting outcomes for two proposals: election of five directors (Proposal 1) and non-binding advisory approval of named executive officer compensation (Proposal 2). The filing presents vote tallies certified by Georgeson LLC as Inspector of Elections, which is the standard format for shareholder vote result disclosures under Item 5.07.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-02
Item 5.02
The filing discloses the appointment of Kathryn Masci and Daniel Plourde as Co-Chief Financial Officers of Grayscale Investments Sponsors, LLC on an interim basis, effective July 2, 2026, with Ms. Masci also appointed as Principal Financial and Accounting Officer of the registrant and as a member of the Board of Managers. While the filing also mentions Edward McGee's departure, the principal disclosed action centers on the appointments of two named executives to critical financial leadership roles. This is material as it affects the registrant's financial reporting and governance structure.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-02
Item 8.01
The disclosure announces stockholder and depositor approval of two material transactions: (1) Columbia Bank MHC's conversion from mutual holding company to fully public stock holding company form (the "Conversion"), and (2) Columbia Financial's simultaneous acquisition of Northfield Bancorp, Inc. The press release explicitly states these are "pending" transactions approved at stockholder and member meetings on June 25 and June 29, 2026, with completion subject to regulatory approvals and minimum share sales. This constitutes material M&A activity under Items 1.01/2.01 of the 8-K taxonomy, as the acquisition of Northfield and the structural reorganization represent significant changes of control and business combination events.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-02
Item 5.02
The filing discloses the appointment of Kathryn Masci and Daniel Plourde as Co-Chief Financial Officers of Grayscale Investments Sponsors, LLC (the sponsor) on an interim basis, effective July 2, 2026, with Ms. Masci also appointed as Principal Financial and Accounting Officer of the registrant and as a member of the Board of Managers. While the filing also mentions Edward McGee's departure, the principal disclosed action centers on the appointment of two named executives to critical financial leadership roles. This is material as it affects the registrant's financial reporting and governance structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-02
Item 5.02
The filing discloses the appointment of Kathryn Masci and Daniel Plourde as Co-Chief Financial Officers of Grayscale Investments Sponsors, LLC (the fund manager) on an interim basis, effective July 2, 2026, with Masci also appointed to the Board of Managers and as Principal Financial and Accounting Officer of the registrant. While the filing also mentions Edward McGee's departure, the principal disclosed action centers on the appointments of two executives to critical financial leadership roles. This is material as it affects the fund's financial oversight and reporting structure.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-02
Item 8.01
VisionWave entered into a strategic Distributor Agreement with Stratonex Defence Technologies on July 1, 2026, appointing Stratonex as its commercialization and sovereign delivery partner for the UK, Europe and other markets. This material commercial partnership establishes a framework for identifying and developing opportunities for VisionWave's defense technologies with government and defense customers, representing a significant operational and strategic business development milestone.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-02
Item 5.02
The filing discloses the appointment of Kathryn Masci and Daniel Plourde as Co-Chief Financial Officers of Grayscale Investments Sponsors, LLC on an interim basis, effective July 2, 2026, with Ms. Masci also appointed as Principal Financial and Accounting Officer of the registrant and as a member of the Board of Managers. While the filing also mentions Edward McGee's departure, the principal disclosed action centers on the two new appointments to critical financial leadership roles. This is material as it affects the registrant's financial reporting and governance structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-02
Item 5.02
The filing discloses the appointment of Kathryn Masci and Daniel Plourde as Co-Chief Financial Officers of Grayscale Investments Sponsors, LLC (the sponsor) on an interim basis, effective July 2, 2026, with Ms. Masci also appointed as Principal Financial and Accounting Officer of the registrant and as a member of the Board of Managers. While the filing also mentions Edward McGee's departure, the principal disclosed action centers on the two new appointments to critical financial leadership roles. This is material as CFO appointments directly affect investor confidence in financial reporting and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-02
Item 5.02
The filing discloses the appointment of Kathryn Masci and Daniel Plourde as Co-Chief Financial Officers of Grayscale Investments Sponsors, LLC on an interim basis, effective July 2, 2026, with Ms. Masci also appointed as Principal Financial and Accounting Officer of the registrant and as a member of the Board of Managers. While the filing also mentions Edward McGee's departure, the principal disclosed action centers on the appointment of two named executives to critical financial leadership roles. This is material as it affects the registrant's financial reporting and governance structure.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-07-02
The filing discloses the termination of Brett Walsh as Chief Accounting Officer (principal accounting officer) effective June 30, 2026, without cause. While the filing also mentions the appointment of Jan Reese as principal accounting officer, the primary disclosed action centers on Walsh's departure from a named executive officer role. The termination of a principal accounting officer is material to investors' assessment of the company's financial reporting structure and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-02
Item 5.02
The filing discloses the appointment of Kathryn Masci and Daniel Plourde as Co-Chief Financial Officers of Grayscale Investments Sponsors, LLC on an interim basis, effective July 2, 2026, with Ms. Masci also appointed as Principal Financial and Accounting Officer of the registrant and as a member of the Board of Managers. While the filing also mentions Edward McGee's departure, the principal disclosed action centers on the two new appointments to critical financial leadership roles. This is material as it affects the registrant's financial reporting and governance structure.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-07-02
Item 5.07
This is a disclosure of shareholder vote results from a special meeting held on July 1, 2026, reporting the certified voting outcomes on two proposals: approval of the company's liquidation and dissolution (2,043,101 votes for, 66,752 against) and adjournment authority (1,975,944 votes for, 116,556 against). The dissolution proposal passed with overwhelming support and represents a terminal event for the registrant. Item 5.07 explicitly governs shareholder vote results, and this disclosure is material as it confirms stockholder approval of the company's liquidation.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-07-02
Item 5.02
The disclosure centers on Zach Scheiner's resignation from the Board of Directors and all Board committees, effective immediately on June 30, 2026. While the filing also mentions Jeff George's appointment to the Audit Committee, the principal action disclosed is Dr. Scheiner's departure. Board-level departures are material governance events affecting investor assessment of the company's leadership and oversight structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-07-02
Item 5.02
The filing discloses two director-level events: the resignation of Dr. Ming-Fu Chiang on June 27, 2026, and the election of Nasim Shomali as a Class II director on July 1, 2026. While both events are disclosed, the principal action emphasized in the Item 5.02 disclosure is the appointment of Shomali, which includes detailed biographical information and her effective date. The resignation is noted as non-contentious and without disagreement. The appointment of a new director to the board is a material governance event affecting the composition of the Company's leadership and oversight structure.
View raw filing on EDGAR →
8-K
Going Concern
confidence 95%
filed 2026-07-02
Item 8.01
The auditor's report explicitly states "Substantial Doubt About the Company's Ability to Continue as a Going Concern," noting that if the Company does not complete an initial Business Combination within 12 months from the IPO closing (by June 26, 2027), it will trigger automatic winding up, dissolution, and liquidation. This is a textbook going-concern disclosure that materially affects investor assessment of the registrant's viability.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-07-02
Item 2.03
Sable Offshore Corp. issued $345.0 million aggregate principal amount of 6.5% Convertible Senior Notes due 2031 on July 2, 2026, pursuant to an indenture with U.S. Bank Trust Company as trustee. The notes are senior, unsecured obligations with conversion rights, redemption provisions, and fundamental change repurchase rights, representing a significant capital-raising transaction.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-02
Item 1.01
Nuvve Denmark, a wholly owned subsidiary of Nuvve Holding Corp., entered into a sale and purchase agreement on June 22, 2026 to acquire all equity interests of BESS Sibiu SRL, a Romanian company developing a 42 MW battery energy storage system. The transaction involves material consideration (approximately €1.68 million in total payments plus assumption of seller loans) and is disclosed under Item 1.01 (Entry into a Material Definitive Agreement), which is the standard Item for acquisition activity. This constitutes a material acquisition of a business asset.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-02
Item 5.02
The filing discloses the appointment of Kathryn Masci and Daniel Plourde as Co-Chief Financial Officers of Grayscale Investments Sponsors, LLC (the sponsor) on an interim basis, effective July 2, 2026, with Ms. Masci also appointed as Principal Financial and Accounting Officer of the registrant and as a member of the Board of Managers. While the filing also mentions Edward McGee's departure, the principal disclosed action centers on the two new appointments to critical financial leadership roles. This is material as it affects the registrant's financial reporting and governance structure.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-07-02
Item 7.01
Rivian disclosed Q2 2026 production (12,613 vehicles) and delivery figures (12,194 vehicles) that exceeded guidance, along with a raised full-year 2026 delivery outlook from 62,000–67,000 to 65,000–70,000 vehicles. While this resembles an earnings release in substance, it is furnished under Item 7.01 (Regulation FD Disclosure) rather than Item 2.02, and the press release explicitly states it contains only production/delivery metrics and forward guidance, not financial results. The announcement is material to investors assessing operational performance and near-term trajectory, but the absence of financial results (revenue, profitability, cash flow) and the Item 7.01 treatment distinguish it from a formal earnings_release, making operational_other the most precise classification.
View raw filing on EDGAR →